TRAINING ENVIRONMENTFictional educational health system · No real patient data
Condition Guide
Condition GuideAssessment, differential, treatment, and monitoring guidance.
Bipolar and Related Disorders
Bipolar care depends on identifying episodic change from baseline, defining the current mood state, assessing safety and psychosis, and distinguishing mania or hypomania from substances, medications, sleep loss, medical illness, trauma, ADHD, personality patterns, and unipolar depression.
Clinical application
Using this resource
Apply these prompts within the simulated clinical context. They support—but do not replace—clinical judgment, supervision, consultation, current guidance, local policy, law, or emergency procedures.
01Use this when
Available history raises a bipolar-spectrum question that could change diagnosis, treatment, or level of care.
02Clarify first
Identify the missing evidence needed to establish—or rule out—a lifetime manic or hypomanic episode.
03Act now
Build a longitudinal timeline and identify the next decision supported by the available evidence.
04Document and communicate
Record the patient-specific evidence supporting the working diagnosis, important alternatives, current episode, severity, psychosis, and safety formulation.
Explain the treatment rationale, shared decisions, monitoring plan, consultation needs, follow-up interval, and information still needed.
05Escalate or consult when
Mania, psychosis, catatonia, severe depression, acute safety concerns, impaired judgment, or rapid deterioration may require a different level of care.
Diagnostic uncertainty, treatment resistance, complex medication exposure, reproductive considerations, or significant medical comorbidity exceeds the current plan or scope.
Diagnostic Features
Define the episode before naming the disorder
Bipolar diagnoses are built from lifetime episodes, not from how the patient presents today. Establish whether a manic or hypomanic episode has ever occurred, then classify. Criteria below summarize DSM-5-TR; consult the manual for full text.
Manic episode
Abnormally and persistently elevated, expansive, or irritable mood with abnormally increased goal-directed activity or energy, most of the day nearly every day for at least one week—or any duration if hospitalization is required.
At least three of the following (four if the mood is only irritable):
Inflated self-esteem or grandiosity
Decreased need for sleep
More talkative or pressured speech
Flight of ideas or racing thoughts
Distractibility
Increased goal-directed activity or psychomotor agitation
Excessive involvement in activities with high potential for painful consequences
Causes marked impairment, requires hospitalization, or includes psychotic features.
Hypomanic episode
The same mood and activity or energy change with the same symptom list and thresholds, lasting at least four consecutive days, most of the day nearly every day.
The change in functioning is unequivocal and observable by others, but is not severe enough to cause marked impairment or require hospitalization, and there are no psychotic features.
Psychosis or hospitalization moves the episode to manic, which changes the diagnosis.
Bipolar I disorder
At least one lifetime manic episode. Hypomanic and major depressive episodes are common but are not required for the diagnosis.
Bipolar II disorder
At least one hypomanic episode and at least one major depressive episode, with no lifetime manic episode. Not a milder form of bipolar I—depressive burden and suicide risk can be substantial.
Cyclothymic disorder
At least two years (one year in children and adolescents) of numerous periods of hypomanic and depressive symptoms that never meet full episode criteria. Symptoms are present at least half the time, with no symptom-free interval longer than two months.
Induced and secondary presentations
Substance- or medication-induced bipolar and related disorder, and bipolar and related disorder due to another medical condition, are separate diagnoses. Establishing the temporal relationship to the exposure or illness is the deciding step.
Rating Scales & Screening
Screen and track, but diagnose clinically
No bipolar instrument establishes a diagnosis. Screens identify who needs a careful longitudinal and collateral assessment; severity measures track change once the diagnosis is made. For guidance on selecting, administering, and interpreting these tools, see the Toolbox's Rating Scales & Screening.
Self-report screen covering thirteen lifetime manic and hypomanic symptom items, plus whether those symptoms co-occurred and how much impairment they caused. A positive screen conventionally requires seven or more symptoms with clustering and meaningful impairment.
Performance depends heavily on setting: it does reasonably well at separating bipolar from unipolar depression among patients already presenting with a mood disorder, and considerably worse as general case-finding. Treat a positive result as a prompt for longitudinal and collateral assessment, never as evidence of diagnosis.
Eleven-item clinician-rated measure of mania severity, scored from patient report over the prior 48 hours combined with observation during the interview. Four items carry double weight to account for poor cooperation in severe illness. Requires training and consistent administration; useful for tracking response during and after an acute manic episode.
Five-item self-rating scale covering mood, self-confidence, sleep, speech, and activity. Brief enough for repeated use, and helpful when a patient is monitoring early warning signs between visits. The APA's DSM-5 Level 2 mania measure ↗ is adapted from it.
Depressive-pole measures
PHQ-9 and similar measures track depressive severity but cannot distinguish bipolar from unipolar depression. A depression score never rules out a history of mood elevation—ask directly and seek collateral.
Assessment & Differential
Build a longitudinal mood timeline
A cross-sectional symptom list is not enough. Establish duration, change from baseline, functional consequences, recurrence, treatment exposure, and collateral evidence.
Mania and hypomania
Assess mood and energy change, decreased need for sleep, speech, thought speed, goal-directed activity, impulsivity, grandiosity, psychosis, judgment, and degree of impairment or hospitalization.
Bipolar depression
Assess depressive syndrome, mixed or activated features, psychosis, catatonia, suicide risk, prior antidepressant response, seasonal or postpartum pattern, and history of mood elevation.
Secondary causes
Evaluate substances, prescribed medications, thyroid and neurologic illness, delirium, sleep deprivation, and other medical contributors when onset, course, or examination raises concern.
Collateral and records
When insight or recall is limited, review prior episodes, hospitalization, medication trials, family history, financial or legal consequences, and observations from trusted supports with appropriate consent.
Key Differential Considerations
Confirm that mood elevation is not produced or imitated elsewhere
Episodicity, duration, and change from baseline separate bipolar illness from conditions that resemble it. For a structured approach to workup, see the Toolbox's Ruling Out Medical Causes.
Medical and neurologic
Hyperthyroidism, Cushing syndrome, delirium, traumatic brain injury, seizure disorders, stroke, multiple sclerosis, frontotemporal and other dementias, autoimmune encephalitis, and infectious causes including HIV and neurosyphilis.
Substances and medications
Corticosteroids, stimulants, sympathomimetics, dopaminergic agents, interferon, cocaine and methamphetamine, intoxication and withdrawal states, and antidepressant-associated switching.
Psychiatric
Unipolar depression with agitation, ADHD, borderline personality disorder, PTSD hyperarousal, substance use disorders, and schizoaffective disorder.
Treatment by Phase
Treat the current episode while planning for recurrence
Choice depends on polarity, severity, mixed features, prior response, comorbidity, reproductive context, interactions, and patient priorities.
Acute mania
Mood stabilizers and/or antipsychotics are selected according to severity, psychosis, agitation, prior response, medical status, and speed of needed effect. Combination treatment may be required.
Bipolar depression
Use treatments with evidence for bipolar depression and avoid assuming that unipolar-depression strategies apply. Antidepressants are not monotherapy for bipolar I depression.
Maintenance
Continue an effective, tolerable strategy when appropriate; address adherence, early warning signs, sleep and rhythm stability, substance use, psychotherapy, supports, and relapse planning.
Advanced treatment
ECT and specialty consultation may be indicated for severe, psychotic, catatonic, treatment-resistant, or urgent presentations, including situations where rapid response is needed.
Safety & Monitoring
Anticipate medication-specific and episode-specific risk
Monitoring must connect the selected treatment with the person's medical risks, life context, and ability to follow the plan. For actual-use histories, interactions, and monitoring workflow, see the Toolbox's Medication Reconciliation & Monitoring.
Lithium
Review renal and thyroid function, calcium, pregnancy considerations, interactions, hydration, toxicity education, and serum concentrations according to the clinical situation. Counsel on sodium and fluid shifts, NSAIDs, thiazides, and ACE inhibitors or ARBs.
Valproate and carbamazepine
Consider hepatic, hematologic, reproductive, teratogenic, interaction, and serum-level issues as applicable. Valproate requires especially careful reproductive risk counseling. Carbamazepine induces multiple enzymes and can lower concentrations of co-prescribed medications, including hormonal contraception.
Use slow titration and educate about rash and urgent evaluation. Reassess titration after interruptions and account for interactions that alter lamotrigine concentrations.
Psychosocial Care
Build a plan that works between visits
Medication is only one part of longitudinal bipolar care. For help matching an approach to the presentation, see the Toolbox's Psychotherapy Modalities.
Psychoeducation
Support recognition of early warning signs, medication understanding, sleep protection, substance-risk awareness, and a specific relapse-response plan.
Structured psychotherapy
CBT, family-focused therapy, interpersonal and social rhythm therapy, and other evidence-informed approaches may support adherence, coping, relationships, and relapse prevention.
Functional recovery
Track work or school participation, finances, driving, relationships, cognition, sleep, and the pace of returning to major responsibilities after an episode.
Shared crisis plan
Identify preferred contacts, early changes, thresholds for urgent evaluation, medication contingencies, access to lethal means, and who will act when insight declines.
Supplements & Mind-Body Approaches
Protect rhythm first, then add adjuncts deliberately
Adjunctive strategies should be tied to a specific goal and reviewed for evidence, safety, interactions, feasibility, and cost. In bipolar illness they support—and never replace—an established mood-stabilizing regimen. For coordinating these into the plan of care, see the Toolbox's Treatment Planning.
Sleep and social rhythm
Regular sleep-wake timing, meal and activity scheduling, and protection against rhythm disruption from shift work, travel, and late-night activity. Sleep loss is both an early warning sign and a precipitant, which makes rhythm stability a core intervention rather than an adjunct.
Bright-light therapy
Has emerging evidence for bipolar depression, generally studied with midday dosing and alongside a mood stabilizer. Monitor for emerging elevation, irritability, and sleep loss, and stop or adjust if activation appears.
Movement and physical health
Graded activity supports mood, sleep, and cardiometabolic health, which matters given the metabolic burden of several bipolar medications. Adapt intensity to current mood state and medical status.
Nutrient and supplement review
Omega-3 products and other supplements have limited and mixed evidence in bipolar illness, mostly at the depressive pole. Review quality, dose, interactions, cost, reason for use, and whether the product is delaying effective treatment.
Clinical Practice Guidelines & Sources
Use current guidance and patient-specific evidence
These sources support clinical reasoning but do not replace a complete assessment, current prescribing information, local policy, consultation, or individualized shared decision-making. The American Psychiatric Association's bipolar guideline dates to 2002 and has not been updated; the sources below reflect current practice.